Drugs / Ghrelin
Ghrelin
also known as
Acyl ghrelin · human ghrelin · unacylated ghrelin · acylated ghrelin · des-octanoyl ghrelin · Lenomorelin · UAG
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03198143 | Oct 2019 → Feb 2021 | obesity disorder | Jenny Tong, MD, MPH | Withdrawn | No outcome recorded |
| Phase 1 | NCT02913703 | Jan 2017 → Dec 2018 | type 2 diabetes mellitus | Jenny Tong, MD, MPH | Completed | No outcome recorded |
| Phase 1 | NCT02953587 | Sep 2016 → Aug 2019 | obesity disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01474785 | Jan 2012 → Jul 2015 | obesity disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00884494 | Aug 2011 → May 2014 | obesity disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05318924 | Feb 2022 → Aug 2024 | major depressive disorder | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1/2 | NCT03358355 | Jun 2016 → Aug 2017 | peripheral arterial disease | Northwestern University | Completed | No outcome recorded |
| Phase 1/2 | NCT00933361 | Jun 2009 → Dec 2011 | cancer of unknown primary site, hypoproteinemia, hypercatabolic | Cantonal Hospital of St. Gallen | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05726240 | Oct 2023 → Dec 2024 | ischemic stroke | Rijnstate Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04558346 | Oct 2020 → Oct 2022 | traumatic brain injury | Michael Rippee | Completed | No outcome recorded |
| Phase 2 | NCT01833078 | Feb → Jun 2013 | — | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT01779024 | Dec 2012 → Jun 2017 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2 | NCT01605435 | May → Dec 2012 | — | University of Pennsylvania | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT06576440 | Sep → Dec 2024 | major depressive disorder | University Hospital Tuebingen | Completed | No outcome recorded |
| — | NCT01729299 | Apr 2013 → Apr 2014 | diabetes mellitus | David Dalessio | Unknown | No outcome recorded |
| — | NCT01531283 | Feb 2011 → Apr 2013 | — | David Dalessio | Unknown | No outcome recorded |
| — | NCT00912587 | Jun 2009 → May 2010 | obesity disorder | Baker Heart and Diabetes Institute | Completed | No outcome recorded |
| — | NCT00139945 | Oct 2005 → Mar 2007 | hypopituitarism | University of Aarhus | Completed | No outcome recorded |
| — | NCT00116025 | Mar 2005 → Jan 2006 | — | University of Aarhus | Completed | No outcome recorded |
| — | NCT00447512 | Mar 2004 → Oct 2007 | major depressive disorder | Max-Planck-Institute of Psychiatry | Completed | No outcome recorded |
Also used as a comparator or background therapy in 14 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01595373 Comparator | Jun → Sep 2012 | — | Esben Thyssen Vestergaard | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT02528422 Comparator | May 2015 → Jan 2018 | renal tubular transport disease | Erling Bjerregaard Pedersen | Unknown | No outcome recorded |
| Phase 1 | NCT02271282 Background | Dec 2014 → May 2016 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02272647 Background | Dec 2014 → Dec 2016 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00771940 Comparator | Oct 2008 → Jan 2009 | — | University of Aarhus | Completed | No outcome recorded |
| Phase 1 | NCT00512525 Comparator | Jan → Oct 2003 | — | University of Aarhus | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05277415 Comparator | Feb 2013 → May 2014 | heart failure | Lars Lund | Completed | No outcome recorded |
| Phase 1/2 | NCT00520884 Comparator | Mar 2007 → Dec 2008 | — | University of Pennsylvania | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04377126 Comparator | Jul 2020 → Jan 2025 | peripheral arterial disease | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT01898611 Comparator | Jul 2013 → Aug 2016 | — | University of Pennsylvania | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00681486 Comparator | Oct 2003 → Jun 2008 | cancer | Göteborg University | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT01209416 Comparator | Jun 2012 → Oct 2014 | hypopituitarism | University of Aarhus | Completed | No outcome recorded |
| — | NCT01190085 Comparator | Apr 2011 → Nov 2012 | alcohol dependence | Brown University | Completed | No outcome recorded |
| — | NCT00763477 Comparator | Apr 2010 → Feb 2011 | cystic fibrosis | Papworth Hospital NHS Foundation Trust | Unknown | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ghrelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03198143 ↗25 |
| Known as | Acyl ghrelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01595373 ↗ |
| Known as | acylated ghrelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00139945 ↗ |
| Known as | des-octanoyl ghrelin | “Use of human unacylated ghrelin (UAG, also called des-octanoyl ghrelin) to study physiology in healthy subjects.” NCT01531283 ↗ |
| Known as | human ghrelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01474785 ↗ |
| Known as | Lenomorelin | ChEMBL registry synonym — accepted as the source's own label CHEMBL500468 ↗ |
| Known as | UAG | “Use of human unacylated ghrelin (UAG, also called des-octanoyl ghrelin) to study physiology in healthy subjects.” NCT01531283 ↗ |
| Known as | unacylated ghrelin | “The GIFT pilot study will investigate the optimal subcutaneous dose and safety of subcutaneously administered unacylated ghrelin in older people with peripheral artery disease (PAD).” NCT03358355 ↗ |
| Action | Activate | “Ghrelin stimulates pituitary GH release by binding to the GHS-R at both hypothalamic and pituitary levels.” NCT00116025 ↗ |
| Modality | Peptide | “Ghrelin is a recently described acylated peptide hormone produced by the enteroendocrine cells of the mucosal epithelial layer in the ventricle.” NCT00116025 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT00512525 ↗ |